Lyme Disease Diagnostic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Lyme disease diagnostics market size in 2026 is estimated at USD 663.67 million, growing from 2025 value of USD 630.03 million with 2031 projections showing USD 860.82 million, growing at 5.34% CAGR over 2026-2031. This report Segments the Industry Into by Test Type (ELISA, Western Blot and More), by Technology (Serologic (Antibody-Based), Molecular Diagnostics and More), by Sample Type (Blood / Serum, Cerebrospinal Fluid and More), by End User (Hospitals & Clinics, Diagnostic Laboratories and More) and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Lyme Disease Diagnostic Market Trends and Insights

Climate-linked Tick Habitat Expansion

Warming winters and longer summers lengthen tick activity seasons and push vectors into higher latitudes, lifting U.S. diagnoses to roughly 476,000 annually and driving test volumes as far south as northern Mexico. Models suggest a 1.5-fold increase in Baltic habitats, alongside a sharp decline in parts of Ukraine, compelling health systems to tailor test menus according to Borrelia species prevalence. Mediterranean and North African nations now report a rise in Borrelia circulation, pressuring suppliers to localize antigen panels for regional strains. Economic projections indicate that a 3 °C temperature rise could swell U.S. healthcare costs to USD 236 million, underlining the persistent demand for accurate early-stage diagnostics.

Rising Adoption of Modified Two-Tier Algorithms (MTTTA)

Clinical laboratories are replacing Western blot confirmation with second-step ELISAs that capture earlier antibody responses, doubling detection sensitivity in some studies without losing specificity. U.S. payers such as Blue Cross NC have started to reimburse MTTTA workflows, easing budget constraints on labs and accelerating uptake. European reference centers are updating guidelines, creating a follow-on effect in emerging Asian laboratories that rely on EU technical standards. Vendors that can bundle first- and second-step kits within a single regulatory filing enjoy stronger purchasing leverage.

High False-Negative Rate of Legacy ELISA Protocols

Traditional two-tier testing can miss up to 50% of early infections, leading clinicians to treat empirically or order repeat tests, raising costs and patient anxiety. France’s SPPT classification illustrates policy acknowledgement of these weaknesses, but many insurers still reimburse only the standard workflow, delaying modern upgrades. False negatives also skew surveillance data, masking actual disease burdens in national registries.

Other drivers and restraints analyzed in the detailed report include:

• FDA Approvals of High-Sensitivity ImmunoBlot & xVFA Rapid Tests
• Home-Collection Kits Boosting Access & Testing Volumes
• Reimbursement Gaps for Multiplex & Urine-Based Assays

Segment Analysis

ELISA generated 45.98% of 2025 revenue, supported by entrenched reimbursement and automated analyzers across clinical labs, yet its high false-negative profile is sparking migration to multiplex arrays growing at a 6.07% CAGR. Western blot remains integral within legacy algorithms, though the Modified Two-Tier ELISA model is gradually curbing blot demand. PCR and NAAT fill a narrow early-infection niche, while lateral-flow cards suit field medicine despite lower sensitivity levels. The Lyme disease diagnostics market size for multiplex microarrays is anticipated to climb markedly as hospitals adopt one-run co-infection panels that improve workflow efficiency. Adoption is paced by payer acceptance and the need for staff training to interpret expanded antigen signatures.

Clinical experience shows protein microarrays lifting sensitivity from 63% to 100% when up to 400 antigens are screened simultaneously. FDA-cleared ImmunoBlot kits with 31-band profiles are eroding Western blot use by matching specificity while reducing laboratory time. As reimbursement codes catch up, ELISA's hold will loosen, yet budget-constrained regional labs may still cling to legacy platforms until depreciation cycles end.

Serology commanded 57.12% revenue in 2025, but digital and AI-augmented platforms are sprinting ahead with 6.62% CAGR by automating result reads and cutting interpretation errors. Molecular assays appeal for direct pathogen detection within the first two weeks of infection, though higher costs limit routine use. Point-of-care cartridges are now integrating machine-learning analytics, enabling physicians to obtain 95.5%-accurate results in under 20 minutes without shipping specimens off-site. The Lyme disease diagnostics market is therefore seeing technology lines blur as vendors hybridize serology with digital overlay or bundle molecular confirmatory tests.

Over the forecast, AI-enabled lateral-flow readers that link to electronic records will become standard in urgent-care clinics. Cloud-based calibration data will ensure consistent sensitivity across devices, while labs migrate to automated strip interpretation, reducing manpower costs. As software attains Class II medical-device status, technology suppliers will pivot from pure reagents to integrated diagnostics-as-a-service subscriptions.

Complete Report Scope:

• By Test Type
  • ELISA
  • Western Blot
  • PCR / NAAT
  • Lateral Flow Assay (Rapid)
  • ImmunoBlot
  • Multiplex Microarray & Others
• By Technology
  • Serologic (Antibody-based)
  • Molecular
  • Point-of-Care Platforms
  • Multiplex Diagnostic Platforms
  • Digital & AI-augmented Diagnostics
• By Sample Type
  • Blood / Serum
  • Cerebrospinal Fluid
  • Urine
  • Skin Biopsy
  • Synovial Fluid
• By End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Homecare / Direct-to-Consumer
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America contributed 42.98% revenue in 2025 as endemic counties expanded westward and northward, with the United States logging about 476,000 annual cases and healthcare costs near USD 1 billion. Canada’s provincial reporting upgrades and Mexico’s emerging tick surveillance reinforce regional growth. FDA rulemaking around laboratory-developed tests introduces near-term compliance costs but longer-term confidence in assay quality.

Asia-Pacific is the fastest-growing region at 7.18% CAGR to 2031, driven by heightened awareness in China, India, and Japan. Diverse Borrelia species challenge imported assay panels, pushing suppliers to localize antigens and validation studies. Public-health agencies across South Korea and Australia have begun joint training with European laboratories to accelerate expertise transfer. Investment in point-of-care formats fits the region’s dispersed rural populations and infrastructure gaps.

Europe maintains strong volumes thanks to harmonized testing guidelines and high clinician familiarity. Germany and France spearhead research output, while Mediterranean states such as Italy and Spain face rising incidence linked to warmer climates and migrating birds South America and parts of Africa sit in early-stage adoption: Argentina has documented human cases, yet under-diagnosis persists due to limited reagent availability and clinician knowledge.

List of Companies Covered in this Report:

• Abbott Laboratories
• Roche
• DiaSorin
• bioMérieux
• QIAGEN
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• ZEUS Scientific
• Trinity Biotech
• Euroimmun (PerkinElmer)
• Quest Diagnostics
• LabCorp
• Igenex
• ArminLabs

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support